Literature DB >> 12552438

Lipoarabinomannan-reactive human secretory immunoglobulin A responses induced by mucosal bacille Calmette-Guérin vaccination.

Robin M Brown1, Orlando Cruz, Michael Brennan, Maria L Gennaro, Larry Schlesinger, Yasir A W Skeiky, Daniel F Hoft.   

Abstract

The ability of 17 recombinant mycobacterial proteins, native antigen 85 complex, lipoarabinomannan (LAM), and Mycobacterium tuberculosis lysate to detect antibody responses induced by bacille Calmette-Guérin (BCG) vaccination and active tuberculosis infection were studied in enzyme-linked immunosorbent assays. Only LAM-reactive serum immunoglobulin G responses were significantly increased in both BCG-vaccinated patients and patients with active tuberculosis (P<.05), and oral BCG vaccination also induced significant increases in LAM-reactive secretory immunoglobulin A (P<.05). LAM-reactive antibody assays can serve as markers of humoral and mucosal immunity in future trials of BCG and newer attenuated mycobacterial vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552438     DOI: 10.1086/368096

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status.

Authors:  Xian Yu; Rafael Prados-Rosales; Elisabeth R Jenny-Avital; Katherine Sosa; Arturo Casadevall; Jacqueline M Achkar
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

Review 2.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

3.  Transcriptional suppression of IL-27 production by Mycobacterium tuberculosis-activated p38 MAPK via inhibition of AP-1 binding.

Authors:  Jidong Zhang; Xuesong Qian; Huan Ning; Christopher S Eickhoff; Daniel F Hoft; Jianguo Liu
Journal:  J Immunol       Date:  2011-04-11       Impact factor: 5.422

Review 4.  Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines.

Authors:  Raymonde B Bekale; Su-Mari Du Plessis; Nai-Jen Hsu; Jyoti R Sharma; Samantha L Sampson; Muazzam Jacobs; Mervin Meyer; Gene D Morse; Admire Dube
Journal:  Pharm Res       Date:  2018-11-08       Impact factor: 4.200

5.  Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies.

Authors:  S de Vallière; G Abate; A Blazevic; R M Heuertz; D F Hoft
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Capsular glycan recognition provides antibody-mediated immunity against tuberculosis.

Authors:  Tingting Chen; Caroline Blanc; Yanyan Liu; Elise Ishida; Sarah Singer; Jiayong Xu; Maju Joe; Elizabeth R Jenny-Avital; John Chan; Todd L Lowary; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 7.  BCG vaccination strategies against tuberculosis: updates and perspectives.

Authors:  Mengjin Qu; Xiangmei Zhou; Hao Li
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

Review 8.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

Review 9.  The protective role of antibody responses during Mycobacterium tuberculosis infection.

Authors:  F Abebe; G Bjune
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

10.  Development of vaccines to control the worldwide tuberculosis pandemic.

Authors:  Daniel F Hoft
Journal:  Mo Med       Date:  2014 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.